About Us

Leadership

CardioCell has an accomplished management team with extensive experience building successful biotech companies. The company’s distinguished Scientific Advisory Board comprises world leaders in cardiology, and its Board of Directors includes prominent pharmaceutical-industry leaders, successful entrepreneurs, influential San Diego businesspeople and cardiology luminaries. The team applies its expertise in cellular and medical research to develop and commercialize new products and technologies.

Sergey Sikora, Ph.D., MBA

CardioCell’s Co-founder, President, and CEO

CardioCell’s Co-Founder, President and CEO Dr. Sergey Sikora has eight years of management and 12 years of biomedical-research experience. He brought his expertise in cardiology diagnostics and therapeutics to CardioCell’s parent company Stemedica in 2013. Before that, Dr. Sikora served as SVP at GenWay, where he established and led the FirstMark Cardiology Diagnostics Division and successfully divested two of the largest divisions of GenWay to Sigma-Aldrich. His career also includes founder and VP of Business Development at MC-Fibers. Dr. Sikora earned his Ph.D. from UCLA, MBA from the Rady School of Management at UC San Diego and B. S. in biochemistry cum laude from UCLA. He currently chairs FirstMark’s Scientific Advisory Board, which comprises top U.S. opinion leaders in cardiology.

Nikolai Tankovich, M.D., Ph.D., FASLMS

President & Chief Medical Officer, Stemedica Cell Technologies
Co-chair, CardioCell

CardioCell’s Co-Founder, Chief Medical Officer and Corporate Oversight. Dr. Nikolai Tankovich is a recognized innovator, licensor, researcher and educator of laser applications in medicine, cancer vaccines, stem-cell therapies and other medical-related disciplines. A founder and director of several corporations, Dr. Tankovich is respected worldwide for his innovative work; he has published more than 60 articles and holds more than 50 U.S. and foreign patents issued and pending. His inventions include devices for laser hair removal and laser skin peeling, non-ablative wrinkle removal and laser lancet (all three licensed and FDA approved). He was the first in the world to propose, invent, develop, patent, build and use a 1.54 micron Er:Glass laser for Fraxel and medical applications. Among his numerous awards and honors is the Gold Kurchatov Medal for the Atomic Science Application in Medicine and Biology awarded by the Atomic Energy Agency in 1998. On Nov. 8, 2011, the Trustees of the Centre for Science and Society appointed Dr. Tankovich as a Legate of the Centre. Dr. Tankovich also has worked on laser diagnosis and surgery of malignant and background uterine cervix diseases and the intraoperation laser diagnosis of early forms of breast cancer. He earned his Ph.D. in BioPhysics from Lomonosov Moscow University, his M.D. from Semashco Medical University in Moscow and his M.S. in Plasma Physics from Moscow University. He also practiced as an oncologist, focusing on new ways to deliver cancer drugs into organs.

Brown

Timothy M. Brown, J.D., M.S., MBA

CardioCell’s Vice President of Intellectual Property

CardioCell’s Vice President of Intellectual Property Timothy M. Brown, J.D., has spent the past 10 years handling intellectual property and patent filings for biotech companies, including Fate Therapeutics Inc. and Stemedica Cell Technologies Inc. Before that he spent five years as a patent examiner in the United States Patent and Trade Office (USPTO). In his career he has prosecuted 13 issued patents, prepared 40 patent applications and negotiated a joint research agreement with a Fortune 500 company. Ideally suited to handle biotech intellectual property, he brings both expertise in law and life sciences. He earned his J.D. cum laude from California Western School of Law; his MBA from California Polytechnic State University, San Luis Obispo; his M.S. in biotechnology from Johns Hopkins University; and his B.S. in cell and molecular biology from San Diego State University. He maintains licenses to practice law in California and before the USPTO.